


**Product Name** : Metarrestin  
**Cat. No.** : PC-35083  
**CAS No.** : 1443414-10-5  
**Molecular Formula** : C<sub>31</sub>H<sub>30</sub>N<sub>4</sub>O  
**Molecular Weight** : 474.608  
**Target** : Eukaryotic Initiation Factor (eIF)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Metarrestin (ML246) is a specific inhibitor of **perinuclear compartment (PNC)**, disrupts PNCs in PC3M-GFP-PTB cells with IC<sub>50</sub> of 0.39 uM, specifically binds **eEF1A2**.

Metarrestin (ML246) reduces PNC prevalence in different human cancer cell lines at 1 uM (IC<sub>100</sub> for PC3M cells) for 24 hours.

Metarrestin (ML246) disrupts the nucleolar structure and inhibits **RNA polymerase (Pol) I** transcription, by interacting with the translation elongation factor eEF1A2 inhibits cancer cell invasion in vitro, suppresses metastatic development in three mouse models of human cancer, and extends survival of mice in a metastatic pancreatic cancer xenograft model with no organ toxicity or discernable adverse effects.

## References

Frankowski KJ, et al. *Sci Transl Med*. 2018 May 16;10(441). pii: eaap8307.

Frankowski K, et al. Discovery and Development of Small Molecules That Reduce PNC Prevalence. Probe Reports from the NIH Molecular Libraries Program [Internet].

Rocchi A, et al. *PLoS Genet*. 2017 Aug 14;13(8):e1006962.

Kuramoto K, et al. *Autophagy*. 2016 Sep;12(9):1460-71.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com